Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia
Abstract
Background Hypertension is a rarely recognized complication of acute lymphoblastic leukemia (ALL). The incidence of hypertension in ALL patients in Indonesia remains unknown, but the most common risk factors are corticosteroid use during induction-phase chemotherapy and renal leukemic infiltration.
Objective To determine the incidence of hypertension in children with ALL, and to assess for associations of high-dose corticosteroids, renal infiltration, and hyperleukocytosis to hypertension.
Methods This was a cross-sectional study involving 100 children aged 2-18 years. Subjects were newly diagnosed ALL patients and those underwent induction-phase chemotherapy in the Pediatric Ward or Outpatient Clinic at Cipto Mangunkusumo or Dharmais Hospitals.
Results Hypertension occurred in 6 (10%) of 60 newly diagnosed ALL patients and 8 (20%) of 40 patients who had received high-dose corticosteroids, but the difference was not statistically significant (OR=2.25; 95%CI 0.72 to 7.07; P=0.239). Hypertension was reported in 8 of 29 subjects who received dexamethasone, but in none of the subjects who received prednisone. However, the difference in these subgroups was also not statistically significant. Renal enlargement was found in 1 of 14 hypertensive patients, but it was not associated with hypertension (OR=0.80; 95%CI 0.52 to 1.24; P=0.417). Hyperleukocytosis was also not associated with hypertension (OR= 0.79; 95% CI 0.20 to 3.11; P=1.000).
Conclusion The incidence of hypertension in ALL patients was 14%. Hypertension is not associated with renal infiltration or hyperleukocytosis. Furthermore, hypertension is not associated with corticosteroid dose, though is found only in subjects who receive dexamethasone. [Paediatr Indones. 2014;54:372-6.].
References
2. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukemia: comparison of prednisone and dexamethasone. Lancet Oncol. 2010;11:1096-106.
3. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol. 1995;17:1-12.
4. Olgar S, Yetgin S, Cetin M, Aras T. Can renal leukemic infiltration cause hypertension in children? J Pediatr Hematol Oncol. 2006;28:579-84.
5. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-54.
6. Attard-Montalto SP, Saha V, Ng YY, Kingston JE, Eden OB. High incidence of hypertension in children presenting with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11:519-25.
7. Louis CU, Butani L. High blood pressure and hypertension in children with newly diagnosed acute leukemia and lymphoma. Pediatr Nephrol. 2008;23:603-9.
8. Feld LG, Corey H. Hypertension in childhood. Pediatr Re. 2007;28:283-98.
9. Saing JH. Hipertensi pada remaja. Sari Pediatri. 2005;6:159- 65.
10. Sekarwarna N, Rachmadi D, Hilmanto D. Rekomendasi tata laksana hipertensi pada anak. Konsensus tata laksana hipertensi pada anak. Unit Kerja Koordinasi Nefrologi IDAI. Jakarta: IDAI; 2011. p.2-5.
11. Supartha M, Suarta IK, Winaya IBA. Hipertensi pada anak. Maj Kedok Indon. 2009;59:221-30.
12. Varda NM, Gregoric A. A diagnostic approach for the child with hypertension. Pediatr Nephrol. 2005;20:499-506.
13. Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al-Musa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003;97:2898-903.
14. Feig DI, Johnson RJ. Hyperur icemia in childhood primary hypertension. Hypertension. 2003;42:247-52.
15. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med. 2006;73:1059-64.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2016-09-08
Published 2014-12-31